Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
Albany Molecular Research
John Ratliff has taken over as CEO at Albany Molecular Research. Previously, Ratliff served for a short period as CEO of LabCorp Diagnostics.
B. Braun Medical
Jean-Claude Dubacher has been named chairman and CEO of B. Braun Medical. Previously, Dubacher served as the leader of commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson in Europe, Middle East and Africa.
Bone Therapeutics has named Miguel Forte as the company’s CEO, succeeding Thomas Lienard. Most recently, Forte was CEO of Zelluna Immunotherapy. He currently serves as chief commercialization officer and chair of the commercialization committee of the International Society of Cellular Therapy.
Joanne Beck has been appointed chief operating officer of Boston Pharmaceuticals. Beck brings to the company her experience from her previous role as executive vice president of global pharmaceutical development and operations at Celgene.
Cerecin has appointed Joseph S. Zakrzewski as chairman of the company’s board of directors. Zakrzewski currently serves as director of Acceleron Pharmaceuticals, Amarin Pharmaceuticals and Sangamo Therapeutics, and he also serves on the board of other private companies.
Elaine Caughey has joined Cygnal as the company’s new chief business officer. Prior to this appointment, Caughey was a consultant to The Blackstone Group and was a senior director of business development at Biogen.
Anthony Rimac has been named chief financial officer and Ann Kapoun has been named senior vice president of R&D at E-Scape. Rimac joined E-Scape after serving as chief financial officer and chief business officer at Chrono Therapeutics. Kapoun previously served as senior vice president of Translational Medicine at OncoMed Pharmaceuticals before joining E-Scape.
Mark Bullimore and April Jasper have joined the scientific advisory board at Eyenovia. Bullimore is currently an adjunct professor at the University of Houston College of Optometry and the associate editor of Ophthalmic and Physiological Optics. Jasper owns and operates a group optometry practice in Florida, Advanced Eyecare Specialists, and is a benedict professor in practice management at Houston College of Optometry.
Dale Pfost has been named chairman and CEO of Lodo Therapeutics. He joins the company from Advent Life Sciences, where he was a general partner, and MicroBiome Therapeutics, of which he was acting CEO. The company also announced the addition of four members to the senior leadership team: Steve Colletti as senior vice president of R&D; Anthony Colasin as senior vice president of business development; Barbara Lindheim as consulting vice president of strategic communications and investor relations; and Sarajane Mackenzie as consulting vice president of human resources and organization development. Colletti came from Merck Research Laboratories as executive director and head of therapeutic modalities; Colasin most recently co-founded Bloom Science; Lindheim joined from BLL Partners, where she was a principal; and Mackenzie previously was president of the Mackenzie Consulting Group and was in charge of human resources at Novo Nordisk.
Shruti Abbato has been named executive vice president of business development for CARMA, a proprietary cell therapy platform from MaxCyte. Previously, Abbato was vice president of business development at Celdara Medical.
Rubius Therapeutics has appointed Christina Coughlin as the company’s chief medical officer. Prior to her new role, Coughlin was chief medical officer at Tmunity Therapeutics.
Steven Geffon has been named chief commercial officer at Science 37. Previously, Geffon was chief commercial officer at Medrio.
Teon Therapeutics has appointed Ken Horne the company’s president and chief operating officer. Horne was previously the CEO of Symic Bio and was a founding member of TauTona Group. He currently serves on the boards of Symic Bio, Afa Science and Advantary.
Namir Hassan has been appointed CEO of Zelluna Immunotherapy after serving as the company’s chief scientific officer. Prior to joining Zelluna, Hassan was with Immunocore.